Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors

Autor: Izquierdo JL, Resano P, El Hachem A, Graziani D, Almonacid C, Sánchez IM

Publikováno v: International Journal of COPD, Vol 2014, Iss default, Pp 1053-1058 (2014)

José Luis Izquierdo, Pilar Resano, Abdulkader El Hachem, Desiré Graziani, Carlos Almonacid, Ignacio M Sánchez Pulmonology Department, Guadalajara University Hospital, Guadalajara, Spain Abstract: While it is relatively well known that the prognosi

Externí odkaz: https://doaj.org/article/96a31a7beff74aefab4d04d9fdc4bd79

Protocolo terapéutico de la agudización asmática

Autor: Mercedes, E., Andrade, I., Almonacid, C.

Publikováno v: In Medicine - Programa de Formación Médica Continuada acreditado October 2019 12(88):5180-5183

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2in vitro

Autor: María Teresa Rugeles, Jaime Alejandro Hincapié-García, Guerra-Almonacid C, W. Zapata-Builes, Lizdany Flórez-Álvarez, Guerra-Sandoval A, María I. Zapata-Cardona, Juan C. Hernandez

IntroductionSARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has caused a pandemic of historic proportions and continues to spread worldwide. Currently, there is no effective therapy against this virus. This article evaluated thein vitroa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29f18da0738d0f398a2405c741a8fc48
https://doi.org/10.1101/2021.03.01.433498

Influence des IgE totales à l’inclusion et des antécédents d’utilisation d’omalizumab sur l’impact du mépolizumab sur la réduction du taux d’exacerbations sévères de l’asthme : résultats de l’étude REALITI-A en vie réelle

Autor: Kihyuk Lee, J., Pollard, S., Liu, M.C., Schleiich, F., Pelaiade, G., Almonacid, C., Heaney, L.G., Chaudhuri, R., Alfonso-Cristancho, R., Jakes, R., Price, R., Maxwell, A., Howarth, P., Hu, S.

Publikováno v: In Revue Française d'Allergologie April 2022 62(3):369-370

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

Autor: Fabbri, Leonardo M., Calverley, Peter M. A., Jose Luis Izquierdo Alonso, Bundschuh, Daniela S., Manja, Brose, Martinez, Fernando J., Rabe, Kf M., Study Groups Abdulla, M., Abdullah, I., Adler, M., Aguilaniu, Albert, I., Almonacid, C., Altés, A., Amaducci, S., Angrill, J., Antonana, J. M., Artner, H., Balint, B., Bantje, T. A., Barbe, F., Bateman, E., Bauchnect, E., Belda, J., Bernabeu, L., Bettendorf, A., Blagden, M., Blanquer, R., Blecher, L., Bonnaud, F., Bourbeau, J., Boyer, G. R., Brotons, C., Bruning, A. H., Bucca, C., Burns, G. E., Von Der Heydt, B. B., Caldwell, Canonica, G. W., Carter, J., Chan, V., Chapman, K. R., Chapman, G., Cheung, D., Chiner, E., Chopra, A., Clini, E., Coulet, P., Craig, B., Croonenborghs, L., Czompó, M., Dal Negro, R. W., Dapper, T., De Graaff, C. S., Ramos Pde, L., De Munck, D. R., Decramer, M., Delobbe, A., Denier, W., De Teresa, L., Dhar, A., Di Maria, G., Dupouy, J., Duschek, G., Echave, J., Esteban, C., Farmer, I. S., Flemale, A., Fletcher, P., Foden, Fouquert, L., Franz, K. H., Frognier, Gagnon, M., Garcia, Mdel M., Garelli, G., Gehling, U., Ginko, T., Glekin, B., Gooding, T., Graham, A., Greillier, P., Greses, J. V., Grillenberger, J., Gross, B., Grygier, H., Gyori, Z., Harper, Henein, S., Heredia, J. L., Hernandez, P., Hoefer, M., Hoffstein, V., Holgate, K., Holler, W., Holub, G., Homik, L., Houle, P. A., Hutter, C., Hyvernat, P., Irusen, E. M., Jackson, A., Janisty, W., Jasnot, J. Y., Joubert, J., Juhasz, G., Jullian, H., Kafe, H., Kelly, P., Kidney, J., Killian, K., Kinch, H., Kirsten, D. L., Kleinecke Pohl, U., Korlipara, K., Krige, L. P., Kroker, A., Kuipers, A. F., Labrecque, M., Larivee, P., Laskowitz, C., Le Merre, C., Lemoigne, F., Ludwig Sengpiel, A., Luengo, M., Luton, R., Macnee, W., Ali, S. M., Maltais, F., Mansur, A., Marciniuk, D., Marin, A., Martin, P., Martinot, J. B., Mazza, F., Bride, M. C., Mcdonald, B., Mckinnon, C., Mclvor, A., Mcnally, D., Mengeot, P. M., Messner, J., Moder, G., Mooney, P., Moretti, A. M., Muller, D., Murio, C., Nardini, S., Nel, A., Ochoa, Saracho Jo, D. E., Paggiaro, P., Paradis, B., Patrick, J., Peche, R., Pellicer, C., Perez, T., Perez, E., De Llano, L. A., Philteos, G., Pieters, W. R., Pigearias, B., Pohl, W., Popovic, R., Prins, M., Querfurt, H., Rajkay, K., Ras, G., Road, J., Roig, J., Roldaan, A. C., Rolke, M., Rozen, D., Sanchez Toril, F., Savani, N., Savary, L., Schiavina, M., Schiesbühl, H., Schreurs, A. J., Schröder Babo, W., Schurmann, W., Seiz, V., Sevette, C., Sharma, R., Shum, C., Damsté, H. E., Smithers, A., Soler, J. J., Steffen, H., Steinhauser, U., Sweilem, M., Tellier, G., Terol, B., Terzano, Claudio, Timar, M., Toma, G., Monserrat, P. T., Trauth, H. A., Valyon, E., Brande Van Den, Van Noord, J. A., Vaquer, J. V., Hernandez Hector, H. V., Vereecken, G., Verkindre, C., Vigh, M., Viljoen, J. J., Vincken, W., Vinkler, I., Visser, S., Volgmann, L., Vorderstrasse, W., Voves, R., Vrancken, F., Weber, H. H., Wielders, P. L., Willoughby, P., Wurtz, J., Yang, W., Zabaleta, M., Zachgo, W., Zanini, A., Zeiner, M., Michael, H., Janistyn, W., Abdulla, R., Terzano, C., Fabbri, L., Barbaro, M. P., Izquierdo, J. L., Ramos, Pde L., Harper, Ochoa

Publikováno v: The Lancet. 374:695-703

Summary Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-seve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d6fa0d4e8d5bb803d0d073cc61197b2
https://doi.org/10.1016/s0140-6736(09)61252-6